ArticleImmunologic research2011
Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?
Article in Immunologic research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Specific immunotherapy in hepatocellular cancer: A systematic review.Journal of gastroenterology and hepatology · 2017Pooled it
- Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study.Human vaccines & immunotherapeutics · 2013Trial
- Immune Assessment Today: Optimizing and Standardizing Efforts to Monitor Immune Responses in Cancer and Beyond.Cancers · 2024Article
- Engaging innate immunity in HIV-1 cure strategies.Nature reviews. Immunology · 2022Review
- Extracorporeal Photochemotherapy: Mechanistic Insights Driving Recent Advances and Future Directions.The Yale journal of biology and medicine · 2020Review
- Platelet P-selectin initiates cross-presentation and dendritic cell differentiation in blood monocytes.Science advances · 2020Article
- Review
- Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti-tumor immunity by promoting the secretion of IFN-γ and IL-2 from T cells.Oncology letters · 2018Article
- Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine.International journal of nanomedicine · 2018Article
- Immunotherapy in triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2017Review
- Cellular immunotherapy for malignant gliomas.Expert opinion on biological therapy · 2016Review
- Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient.BMC cancer · 2016Article
- DC generation from peripheral blood mononuclear cells in patients with chronic myeloid leukemia: Influence of interferons on DC yield and functional properties.Human vaccines & immunotherapeutics · 2016Article
- Dendritic cell-based vaccine efficacy: aiming for hot spots.Frontiers in immunology · 2015Review
- Article
- Stressful presentations: mild cold stress in laboratory mice influences phenotype of dendritic cells in naïve and tumor-bearing mice.Frontiers in immunology · 2014Article
- Dendritic cells in cancer immunotherapy clinical trials: are we making progress?Frontiers in immunology · 2013Review
- Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.BMC immunology · 2013Article
- Human dendritic cell subsets in vaccination.Current opinion in immunology · 2013Review
- Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies.Expert review of vaccines · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Dendritic cells (DCs) are the most powerful immunostimulatory cells specialized in the induction and regulation of immune responses. Their properties and the feasibility of their large-scale ex vivo generation led to the application of ex vivo-educated DCs to bypass the dysfunction of endogenous DCs in cancer patients and to induce therapeutic anti-cancer immunity. While multiple paradigms of therapeutic application of DCs reflect their consideration as cancer "vaccines", numerous features of DC-based vaccination resemble those of autologous transplants, resulting in challenges and opportunities that distinguish them from classical vaccines. In addition to the functional heterogeneity of DC subsets and plasticity of the individual DC types, the unique features of DCs are the kinetic character of their function, limited functional stability, and the possibility to imprint in maturing DCs distinct functions relevant for the induction of effective cancer immunity, such as the induction of different effector functions or different homing properties of tumor-specific T cells (delivery of "signal 3" and "signal 4"). These considerations highlight the importance of the application of optimized, potentially patient-specific conditions of ex vivo culture of DCs and their delivery, with the logistic and regulatory implications shared with transplantation and other surgical procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.